Inozyme Pharma, Inc.: Business Overview, Financials & Competitive Analysis
Inozyme Pharma, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Acquisition-driven valuation with binary clinical catalyst in Q1 2026 creates asymmetric risk-reward, though deal scrutiny and potential legal challenges introduce execution uncertainty. The company demonstrates promising clinical progress with strong safety profiles and no patient dropouts in its pivotal trial. However, the imminent acquisition by BioMarin eliminates near-term stock.
What is Inozyme Pharma, Inc.'s industry? Inozyme Pharma, Inc. (inozyme.com) operates in Biopharmaceutical - Rare Diseases / Enzyme Replacement Therapy. AskCyborg classifies Inozyme Pharma, Inc. under Biopharmaceutical - Rare Diseases / Enzyme Replacement Therapy in its company registry.
Inozyme Pharma is a clinical-stage biopharmaceutical company developing therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate, INZ-701, is a soluble, re...
Cyborg Score thesis
Acquisition-driven valuation with binary clinical catalyst in Q1 2026 creates asymmetric risk-reward, though deal scrutiny and...
Read the full analyst-debate transcript →Get the Latest Inozyme Pharma, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeInozyme Pharma, Inc. Overview
Pro stress-test →Inozyme Pharma is a clinical-stage biopharmaceutical company developing therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis. BioMarin Pharmaceutical has agreed to acquire Inozyme Pharma for $4.00 per share in an all-cash transaction valued at approximately $270 million, adding INZ-701, a Phase 3 enzyme replacement therapy.
Strategic Profile
Pro stress-test →INZ-701 targets a rare, serious, and progressive genetic condition that affects blood vessels, soft tissues and bones, with increased cardiovascular mortality risk and severe rickets/osteomalacia in children and adults. The ENERGY 3 pivotal trial for INZ-701 completed enrollment in January 2025, with topline data anticipated in Q1 2026. Analysts project peak annual sales of $400–$600 million by the mid-2030s.
Competitive Landscape
Pro stress-test →ENPP1 Deficiency is an ultra-orphan disease affecting roughly 2,000 patients globally with no approved treatments. INZ-701 positions as potential first-in-disease therapy in a highly specialized rare disease space with limited direct competition. The company is expanding INZ-701 evaluation into additional indications including ABCC6 Deficiency and calciphylaxis.
Industry Context
Inozyme Pharma, Inc. operates in Biopharmaceutical - Rare Diseases / Enzyme Replacement Therapy.
Key facts
Founded: 2015 · Headquarters: Boston, Massachusetts